Detalhe da pesquisa
1.
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Pediatr Res
; 94(3): 1035-1043, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36899125
2.
Correction: Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Pediatr Res
; 95(4): 1159, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853068
3.
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Jpn J Infect Dis
; 76(3): 174-182, 2023 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724939
4.
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
Hum Vaccin Immunother
; 18(1): 1-10, 2022 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34085900
5.
Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
Vaccine
; 40(10): 1421-1438, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35144847
6.
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.
Vaccine
; 38(28): 4405-4411, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387012
7.
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
Vaccine
; 38(19): 3560-3569, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209248
8.
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.
Hum Vaccin Immunother
; 16(6): 1306-1312, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233959
9.
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.
Hum Vaccin Immunother
; 16(6): 1299-1305, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233961
10.
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.
Vaccine
; 38(33): 5194-5201, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32565344
11.
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
Hum Vaccin Immunother
; 16(6): 1292-1298, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209015
12.
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Pediatr Infect Dis J
; 39(10): 955-960, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852352
13.
Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
Pediatr Infect Dis J
; 38(3): 317-322, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408001
14.
Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
Hum Vaccin Immunother
; 15(3): 658-668, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30513252
15.
Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
Pediatr Infect Dis J
; 37(8): 823-830, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29762363
16.
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule.
Pediatr Infect Dis J
; 36(1): 87-93, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27753797
17.
DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
Expert Rev Vaccines
; 16(2): 85-92, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27996332
18.
Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age.
Pediatr Infect Dis J
; 36(3): 319-325, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27879555
19.
A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
Pediatr Infect Dis J
; 36(11): e272-e282, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719500
20.
Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
Vaccine
; 33(51): 7188-7193, 2015 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26555348